Overview
CLDX market data
Price History
CLDX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.90 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.87 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -147,788.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $20.19 – $45.14 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.4B · P/B 3.42 · P/S 21,272.56.
Company News
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46Benzinga · Aug 7, 2026, 6:52 PM
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53Benzinga · Aug 7, 2026, 10:50 AM
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K EstimateBenzinga · Aug 6, 2026, 9:57 PM
Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72Benzinga · Jul 29, 2026, 4:10 PM
Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48Benzinga · Jul 22, 2026, 6:50 PM
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $40Benzinga · Jul 22, 2026, 6:32 PM
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga · Jul 22, 2026, 1:19 PM
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $61Benzinga · Jul 22, 2026, 1:11 PM
Celldex Therapeutics shares are trading lower after the company reported that the Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis did not meet its primary endpoint. Also, Canaccord Genuity lowered its price target on the stock from $62 to $60.Benzinga · Jul 22, 2026, 11:58 AM
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis StudyBenzinga · Jul 22, 2026, 11:29 AM